Neuroimaging and Analytical Methods for Studying the Pathways from Mild Cognitive Impairment to Alzheimer’s Disease: Protocol for a Rapid Systematic Review by Ahmadzadeh, Maryam et al.
PROTOCOL Open Access
Neuroimaging and analytical methods for
studying the pathways from mild cognitive
impairment to Alzheimer’s disease: protocol
for a rapid systematic review
Maryam Ahmadzadeh1,2,3, Gregory J. Christie1,2,3, Theodore D. Cosco4,5 and Sylvain Moreno1,2,3*
Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder commonly associated with deficits of
cognition and changes in behavior. Mild cognitive impairment (MCI) is the prodromal stage of AD that is defined
by slight cognitive decline. Not all with MCI progress to AD dementia. Thus, the accurate prediction of progression
to Alzheimer’s, particularly in the stage of MCI could potentially offer developing treatments to delay or prevent the
transition process. The objective of the present study is to investigate the most recent neuroimaging procedures in
the domain of prediction of transition from MCI to AD dementia for clinical applications and to systematically
discuss the machine learning techniques used for the prediction of MCI conversion.
Methods: Electronic databases including PubMed, SCOPUS, and Web of Science will be searched from January 1,
2017, to the date of search commencement to provide a rapid review of the most recent studies that have
investigated the prediction of conversion from MCI to Alzheimer’s using neuroimaging modalities in randomized
trial or observational studies. Two reviewers will screen full texts of included papers using predefined eligibility
criteria. Studies will be included if addressed research on AD dementia and MCI, explained the results in a way that
would be able to report the performance measures such as the accuracy, sensitivity, and specificity. Only studies
addressed Alzheimer’s type of dementia and its early-stage MCI using neuroimaging modalities will be included.
We will exclude other forms of dementia such as vascular dementia, frontotemporal dementia, and Parkinson’s
disease. The risk of bias in individual studies will be appraised using an appropriate tool. If feasible, we will conduct
a random effects meta-analysis. Sensitivity analyses will be conducted to explore the potential sources of
heterogeneity.
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Discussion: The information gathered in our study will establish the extent of the evidence underlying the
prediction of conversion to AD dementia from its early stage and will provide a rigorous and updated synthesis of
neuroimaging modalities allied with the data analysis techniques used to measure the brain changes during the
conversion process.
Systematic review registration: PROSPERO,CRD42019133402
Keywords: Systematic review, Alzheimer, Mild cognitive impairment, Prediction, Conversion, Modality,
Neuroimaging, Machine learning, Data analysis
Background
Dementia causes deterioration of cognitive function that is
expected to affect approximately 65.7 million individuals
around the world by 2030 [1]. Although there are several
types of dementia, Alzheimer’s disease (AD) is the most
common type, which comprises around 60-80% of demen-
tia cases [2]. This disease has not only consequences on a
social level in terms of costs but also more importantly on
patient’s and caregiver’s quality of life [3]. AD can be cate-
gorized into three phases: (1) the preclinical phase, which
may begin years before diagnosis as AD [4]; (2) mild cogni-
tive impairment (MCI), the transitional stage between nor-
mal cognition and AD, during which individuals
experience slight impairments in their cognitive function
and memory, while maintaining the ability to perform their
daily activities [5]; (3) AD, that is indicated by decline in
cognitive function and changes in behavior [2]. Although
some individuals with MCI remain stable or return to nor-
mal cognition, progression to AD occurs at a rate of about
10% to 15% per year [6, 7]. Those cases where individuals
convert from MCI to AD are termed progressive MCI
(pMCI) and those cases where cognition remains stable are
termed stable MCI (sMCI). Currently, it is not entirely
understood why some individuals experience pMCI and
convert to AD. Therefore, in a clinical context, it is not
clear which patients with MCI would benefit the most
from clinical interventions and cognitive rehabilitation pro-
grams. The ability to predict who will progress to AD
dementia from MCI will allow identifying the individuals
who could benefit the most from clinical trials. As a result,
early prediction of AD could provide the potential thera-
peutic windows to slow down the progression process [8].
To predict the conversion to Alzheimer’s, researchers
have followed several directions. Some studies investigated
genetic assessments or biological markers such as those in
cerebrospinal fluid (CSF) and many of them explored neu-
roimaging modalities like electroencephalography (EEG)
and functional imaging [9–12]. The main limitation of
CSF biomarkers is that their collection requires the inva-
sive procedure of lumbar puncture which is not recom-
mended in routine clinical assessments [13, 14].
Many studies show that AD pathology can be predicted
with high accuracy using neuroimaging modalities [15,
16]. These modalities mainly include structural magnetic
resonance imaging (sMRI), functional magnetic resonance
imaging (fMRI), positron emission tomography (PET),
functional single-photon emission computed tomography
(SPECT), and electroencephalography (EEG) [16–18]. In
each modality, researchers measure the changes of differ-
ent biomarkers (i.e., changes in gray matter, white matter,
or cortical thickness in MRI modality) during the conver-
sion process to predict the conversion from MCI to AD
[19, 20]. Both structural and functional magnetic reson-
ance imaging modalities are noninvasive and non-
radiation tools for detecting neuronal degeneration at the
early stage of AD and investigating progressive brain
changes from MCI to AD [21]. Researchers have used
PET modalities to investigate metabolic changes during
AD progression. In comparison with MRI, PET studies
are more invasive and less available, due to their radiation
exposure and higher costs [22]. The other type of modality
is EEG, which is a non-invasive, extensively available, and
low-cost procedure to record the electrical activity of the
brain. The findings of a recent study show that EEG co-
herence is a great predictor of AD progression [23]. Since
each modality has its advantages and limitations, it can be
expected that the combination of different modalities
could provide complementary information [9, 24, 25].
After the identification of informative AD modalities,
appropriate data analysis techniques are required to be
applied to data to assess the conversion from MCI to
AD [26–28]. Recent decades have shown significant
growth in the emergence of machine-learning (ML) and
pattern-recognition techniques as the effective tools for
analyzing brain images to develop the prognosis of AD,
while the pathological signs are not observable by visual
assessments [5].
In this study, we will conduct a rapid systematic re-
view of the most recent studies that have investigated
the progression from MCI to AD dementia using neuro-
imaging modalities along with machine learning tech-
niques. Thus, the state of the art in neuroimaging and
neurodegenerative assessment is presented. There will
be two main fields of synthesis in this review. Firstly, we
will explore the most recent neuroimaging procedures
used to predict the conversion from MCI to AD for
Ahmadzadeh et al. Systematic Reviews            (2020) 9:71 Page 2 of 6
clinical applications. Secondly, we will systematically in-
vestigate the machine learning techniques applied to cre-
ate predictive models for the classification of individuals
with progressive MCI versus stable MCI.
Methods/design
Study design
This is the study protocol for a rapid (systematic) review. A
rapid (systematic) review is a form of knowledge synthesis
in which components of the systematic review process are
simplified or omitted to produce information in a timely
manner [29]. This systematic review protocol has been pre-
pared in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses-Protocols
(PRISMA-P) statement [30] (The PRISMA-P checklist is
included as Additional file 1). This protocol is registered
on PROSPERO (international prospective register of sys-
tematic reviews) (registration number CRD42019133402).
This review will gather evidence on the effectiveness of
neuroimaging modalities and data analysis techniques used
to predict conversion from MCI to AD.
Search methods
We will systematically search the following electronic
databases: PubMed/MEDLINE, SCOPUS [31], and Web
of Science to provide a rapid systematic review of the
eligible studies. We have selected these databases ac-
cording to preliminary searches and consultation with
experts in this field. The reference lists of included arti-
cles will be manually searched to identify any missing
studies. Keywords related to predicting the progression
from MCI to AD will be used. We will use both Medical
Subject Headings (MeSH) and keyword searches to in-
crease the sensitivity of the search where possible. Add-
itional file 2 shows the search strategy for PubMed/
MEDLINE database.
Screening and selection procedure
Electronic search results will be downloaded into the
Zotero software which is a platform that streamlines the
screening of systematic reviews [32]. Two reviewers will
independently screen all articles identified from the
search. First, all titles and abstracts of the articles
returned from initial searches will be screened based on
the inclusion/exclusion criteria. Next, full texts will be
examined in detail for applicability. If the relevance of
an abstract is unclear, it will be reviewed with full-text
screening [33]. Any disagreement between reviewers will
be resolved by discussion to meet a consensus. A third
reviewer will be consulted to decide if consensus is not
achieved initially.
Eligibility criteria
Studies will be included in the review paper, if (1) address
research on Alzheimer’s disease dementia and MCI; (2)
focus on the prediction of conversion from MCI to AD
dementia; (3) explain the results in a way that we would
be able to report the performance measures such as the
accuracy, sensitivity, and specificity of predicting conver-
sion to AD dementia; (4) describe applied data analysis
techniques in sufficient detail to enable replication; (5) use
neuroimaging modalities in their research; and (6) are
published from January 1, 2017, to the date of search com-
mencement. Since the review paper has focused on a
cutting-edge research topic that is fast-paced and develop-
ing quickly, we limited the search to examine only the
most recent studies, not the outdated ones. Language or
publication status restrictions will not be imposed and if
necessary, the search will be translated. The unit of assess-
ment will be per-lesion. As the aim of this study is to in-
vestigate the transition from MCI to AD dementia, we will
exclude articles address research on other types of demen-
tia such as frontotemporal dementia, Lewy body dementia,
vascular dementia, Huntington’s disease, and Parkinson’s
disease and mixed dementia. Ineligible studies (e.g., con-
ference proceedings, editorial, secondary data analyses, re-
view articles, book reviews) will be excluded as well.
Data extraction process
We are interested in investigating the studies addressed
prediction of progression from MCI to AD dementia
using neuroimaging modalities along with machine learn-
ing techniques. Thus, we will explore various modalities
that have been using in the selected studies as well as data
analysis techniques in the early prediction of AD demen-
tia. To achieve this goal, you will develop a bespoke data
extraction excel template that captures all the relevant in-
formation, and this will be piloted with two independent
researchers before it is taken to the full-text extraction.
The following information from each included study will
be extracted: (1) author(s); (2) year of publication; (3)
source of data; (4) follow-up period (conversion period);
(5) sample size (i.e., number of participants with stable
MCI, progressive MCI ); (7) modalities; (8) neuroimaging
features; (9) data analysis techniques, and (10) perform-
ance of results in terms of accuracy, sensitivity, specificity,
and area under curve (AUC) if available. We will contact
authors of primary publications and/or collaborators for
clarification if data in an included study is unclear or miss-
ing. Discrepancies between reviewers in the extracted data
phase will be resolved with discussion. If consensus is not
achieved initially a third reviewer will be involved.
Quality and risk of bias assessment
We will use the quality in prognostic studies (QUIPS)
tool to assess the risk of bias (internal validity) of
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included studies [34]. All articles will be assessed inde-
pendently by two reviewers within the six domains in-
cluding study participation, study attrition, prognostic
factor measurement, outcome measurement, study con-
founding, and statistical analysis and reporting. Each re-
viewer will insert relevant information from each paper
in a table that would be rated as high, moderate, or low
risk of bias [35]. Discrepant scores will be resolved by
discussion or consulting a third member of the group.
Data synthesis and gap identification
First, the results of the identified studies will be de-
scribed and summarized in a narrative synthesis. In this
context, we will synthesize primary studies to explore
heterogeneity descriptively rather than statistically such
as structured narratives or summary tables. A descriptive
summary will be provided focusing on the investigation
of neuroimaging modalities, data analysis techniques,
and outcomes. Data synthesis will help us to identify
gaps in the evidence, areas of strength, and fields in need
of improvement related to methodological development,
modalities, and features identification to achieve the
main objective of predicting progression from MCI to
AD dementia. Second, a quantitative synthesis (i.e.,
meta-analysis) will be performed if there are sufficient
data and if a group of studies is sufficiently homogenous
in terms of modalities, data analysis methods, or per-
formance to provide a meaningful summary. We will as-
sess heterogeneity by the Cochran Q test and I2 statistic
[36, 37]. For each factor, random effects meta-analysis
using the method by DerSimonian and Laird will be
conducted to measure the standard mean difference be-
tween subjects with progressive MCI and stable MCI.
Furthermore, publication bias will be evaluated using
visual inspection of the funnel plots and the Egger’s
asymmetry test, with P values < 0.1 considered signifi-
cant. For any quantitative analyses, we will conduct sen-
sitivity analyses including a high risk of bias studies. We
will use the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach to as-
sess the quality of evidence for individual comparisons
and outcomes using [38].
Discussion
This rapid review will provide a knowledge synthesis of
the potential neuroimaging modalities as well as data
analysis techniques used in recent years to predict the
progression from mild cognitive impairment to Alzhei-
mer’s disease dementia. Additionally, we will emphasize
the essential need for early prediction of AD to provide
the potential therapeutic windows for this progressive
disease. Basically, the two main contributions of our re-
view will be as following: (1) an investigation of the re-
cent neuroimaging modalities used for prediction of AD
dementia progression, and (2) a discussion of data ana-
lysis techniques employed to measure the brain changes
during the conversion process. The review will merge
different domains of cognitive science, neuroscience, and
computer science to benefit the research focused on the
prediction of Alzheimer’s disease in the early stage of
MCI. The results of the review will identify possible gaps
in the current studies and brings knowledge for further
research. Any amendments or modifications made in the
protocols will be outlined and reported in the final pa-
pers. We anticipate a limitation of this study will be a
lack of complete and in-depth reporting of biomarkers,
data analysis techniques, and data sources in the predic-
tion of AD dementia studies.
Another limitation of this study is that we restricted
our search to the studies published from January 1,
2017, to the date of search commencement, which
would be a relatively short timeline. The reason behind
this consideration is that the review paper has focused
on a cutting-edge research topic that is fast-paced and
developing quickly, we aimed to examine only the most
recent studies, not the outdated ones.
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